Merck acquiring Cidara Therapeutics in $9.2bn deal
American multinational pharmaceutical company Merck has signed a definitive agreement to acquire biotech group Cidara Therapeutics, valuing the deal at about $9.2 billion The deal is expected to close in 1Q 2026 once customary antitrust and tender-offer conditions are met. Both boards have approved the transaction. At the centre of the deal is CD388, Cidara’s first-in-class, long-acting antiviral engineered to…